What is Chardan Capital's Forecast for MNPR FY2025 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Monopar Therapeutics in a report issued on Tuesday, June 24th. Chardan Capital analyst K. Nakae forecasts that the company will earn ($2.02) per share for the year. Chardan Capital has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.87) EPS.

MNPR has been the topic of several other reports. Piper Sandler restated an "overweight" rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.50.

Monopar Therapeutics Stock Performance

MNPR opened at $35.01 on Friday. The company has a fifty day moving average price of $36.87 and a two-hundred day moving average price of $34.68. The firm has a market capitalization of $214.26 million, a PE ratio of -10.06 and a beta of 0.99. Monopar Therapeutics has a 52 week low of $1.72 and a 52 week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.27.

Insider Activity at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the fourth quarter worth $23,435,000. Adage Capital Partners GP L.L.C. acquired a new position in Monopar Therapeutics in the 4th quarter worth $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the 4th quarter worth $11,247,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter worth about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.